AML
| FAB Subtype . | Common Phenotype . | Comments/Variations . | Potentially Associated Genetic Abnormalities . |
|---|---|---|---|
| M0 | DR, CD13, CD33, CD34, CD7−/+, TdT−/+ | Blasts >90% | |
| Lymphoid markers | Complex changes particularly involving 5 or 7 | ||
| t(9; 22) possible | |||
| M1 | Similar to MO except CD15−/+ | Blasts >90% | No consistent alteration |
| M2 | DR, CD13, CD33, more CD15 and less CD34 than M1 | Blasts <90% | |
| Isolated CD19 in AML with maturation | t(8; 21) more likely | ||
| M3 | DR(−), CD13, CD15, CD33, CD34−/+, CD2 occasionally | Strong SSC except M3v | If t(15; 17) (−) cytogenetically, RAR rearrangement molecularly, consider variants, t(11; 17) |
| CD2(+), DR(−) in maturing AML consider M3 | |||
| M4, M5 | DR, CD15, CD14+/−, CD33 > CD13, CD34−/+, CD4 weak | CD2, consider M4E0 | 11q23 rearrangements in 35% Inv(16) or t(16; 16) in most M4E0 |
| M6 | DR, CD13−/+, CD33+/−, CD34, CD45 weak | Mature forms express glycophorin | No consistent alteration |
| Frequently in dysplastic background | −7 or del(7q) and/or −5 or del(5q) | ||
| M7 | DR−/+, CD33+/−, CD34, CD41, CD61 | Phenotyping critical, beware of platelet adhesion to blasts | Most frequent FAB subtype in trisomy 21 children |
| FAB Subtype . | Common Phenotype . | Comments/Variations . | Potentially Associated Genetic Abnormalities . |
|---|---|---|---|
| M0 | DR, CD13, CD33, CD34, CD7−/+, TdT−/+ | Blasts >90% | |
| Lymphoid markers | Complex changes particularly involving 5 or 7 | ||
| t(9; 22) possible | |||
| M1 | Similar to MO except CD15−/+ | Blasts >90% | No consistent alteration |
| M2 | DR, CD13, CD33, more CD15 and less CD34 than M1 | Blasts <90% | |
| Isolated CD19 in AML with maturation | t(8; 21) more likely | ||
| M3 | DR(−), CD13, CD15, CD33, CD34−/+, CD2 occasionally | Strong SSC except M3v | If t(15; 17) (−) cytogenetically, RAR rearrangement molecularly, consider variants, t(11; 17) |
| CD2(+), DR(−) in maturing AML consider M3 | |||
| M4, M5 | DR, CD15, CD14+/−, CD33 > CD13, CD34−/+, CD4 weak | CD2, consider M4E0 | 11q23 rearrangements in 35% Inv(16) or t(16; 16) in most M4E0 |
| M6 | DR, CD13−/+, CD33+/−, CD34, CD45 weak | Mature forms express glycophorin | No consistent alteration |
| Frequently in dysplastic background | −7 or del(7q) and/or −5 or del(5q) | ||
| M7 | DR−/+, CD33+/−, CD34, CD41, CD61 | Phenotyping critical, beware of platelet adhesion to blasts | Most frequent FAB subtype in trisomy 21 children |
Abbreviations: +/−, variable, more often positive; −/+, variable, more often negative; (−), negative; DR, HLA-DR; SSC, side scatter; RAR, retinoic acid receptor; M3v, microgranular variant.